EME Equity Market – April 2018 Market performance – ASE gained the most in April, while the ISE30 lost the most. The MSCI EME dropped by 3.2% mom in EUR terms. The ASE index (+10% mom) reported the largest rate of return, followed by the Polish WIG20 index (+2.9%), and the BUX (+2.7% mom); while the Turkish ISE30 lost -10.4% mom, followed by the Russian MICEX (-6.3% mom), and the Czech PX index (-1.4% mom). The Romanian BET index stayed fairly flat (-0.1% mom).
HEADLINES: * Rosneft: major steps towards boosting shareholder value (upgraded to BUY) * EME Macro/Strategy: good news! (Alas, the best is still behind us) * Surgutneftegas: 1Q18 RAS results - broadly in line, accrued dividend on preferred shares at RUB 0.6 * Emlak Konut: strong 1Q18 P&L, but tenders and unit sales remain crucial POSITIVE * Podravka: 1Q18 results strong compared to 1Q17 and 4Q17 NEUTRAL * NIS: 1Q18 results significantly below expectations NEGATIVE * Nostr...
EME Equity Market – March 2018 Market performance – only Romania and Prague in positive territory. The MSCI EME lost 5.8% mom in March, continuing the negative trend after February’s 1.1% contraction. The Romanian BET index was the best performer in March, +3.1%, while Prague’s PX index remained broadly flat, recording a small gain of 0.3%. On the negative side, the Turkish ISE30 performed poorly, losing 9.1%, followed by the Warsaw WIG20, -7.3%. The Greek ASE index fell by 6.6% and Mosc...
HEADLINES: * Petkim: 4Q results, much better than expected POSITIVE * Enka Insaat: 4Q17 review - broadly as expected NEUTRAL * Moscow Exchange: recommends RUB 5.47 DPS for 2H17 POSITIVE * Moscow Exchange: reveals capex and opex guidance for 2018E NEUTRAL * Podravka: 2017 results burdened by one-offs * German and Italian elections: early results * Polish banks: FX mortgage saga - commission to meet in mid-March NEUTRAL * Alior Bank: public salary cap act still not impos...
​Podravka Group processes food and manufactures pharmaceuticals. Podravka d.d. is one of the largest branded food producer in Central, Eastern and South-Eastern Europe, while Belupo is second largest pharmaceutical company in Croatia.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.